Ulcerative Colitis

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Findings suggest cuffitis after ileal pouch-anal anastomosis is linked to long-term complications including strictures and fistulas, potentially contributing to a greater risk of pouch failure.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.

Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.

Findings demonstrate a similar postoperative safety profile for both tofacitinib and biologics in patients with medically refractory ulcerative colitis undergoing colectomy.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.

A high intake of fish and vegetables at 1 year of age was associated with a lower risk of IBD, while consuming sugar-sweetened beverages was linked to a greater risk of developing IBD.

Findings from the retrospective cohort study suggest an increased prevalence of advanced kidney disease among individuals with Crohn disease and ulcerative colitis.

Patients ≥ 65 years of age experienced similar rates of remission and adverse events compared to their younger counterparts, with no significant difference in change in renal function observed between the 2 groups.

Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.

The guideline includes 9 conditional recommendations to support practitioners in the management of pouchitis and inflammatory pouch disorders.

The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.